Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported an option exercise and related share sale. He exercised stock options for 2,032 shares of common stock at an exercise price of $3.57 per share and sold 2,032 shares in an open-market transaction at a weighted average price of $7.01 per share.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on February 2, 2026, designed to sell shares received from option exercises only as needed to fund exercise costs and estimated tax withholding. Following these transactions, he directly holds 81,258 shares of common stock and 50,168 stock options.
Shattuck Labs, Inc. chief medical officer Arundathy N. Pandite reported an open-market sale of 30,000 shares of common stock. The shares were sold at a weighted average price of $6.61 per share, in multiple trades between $6.41 and $7.03. Following the transaction, she directly holds 166,219 shares. The sale was effected under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026.
Shattuck Labs, Inc. director and Chief Executive Officer Taylor Schreiber reported acquiring 25,610 shares of common stock through the exercise of warrants at a conversion price of $1.0846 per share. Following these transactions, Schreiber holds 122,222 shares directly and 2,610,750 shares indirectly through Houghton Capital Holdings, LLC.
Shattuck Labs, Inc. executive Stephen Stout reported a small tax-related share disposition. On this Form 4, 968 shares of Common Stock were withheld at $6.85 per share to cover tax obligations, a non-market transaction. After this withholding, Stout directly holds 80,561 shares of Shattuck Labs common stock.
Shattuck Labs reported a first-quarter 2026 net loss of $14.8 million, slightly wider than $13.7 million a year earlier, as it expanded spending on its lead inflammatory bowel disease candidate SL-325. Research and development expenses rose to $10.9 million, while general and administrative costs were stable at $4.6 million.
Cash and cash equivalents increased to $90.4 million from $54.2 million at year-end 2025, helped by $20.6 million of common stock sales through an at-the-market program and $5.4 million of warrant exercises. Management believes this cash is sufficient to fund operations for at least 12 months as it completes a Phase 1 trial of SL-325 and prepares a Phase 2 trial in Crohn’s disease.
Shattuck Labs, Inc. reported first quarter 2026 results and business updates. The company is running a Phase 1 trial of its lead DR3 blocking antibody SL-325, has completed enrollment in all single- and multiple-ascending dose cohorts, and plans to share detailed data in the second quarter of 2026. Subject to positive Phase 1 data and regulatory alignment, a Phase 2 trial in Crohn’s disease is expected to start in the third quarter of 2026, and a lead DR3-based bispecific antibody has entered IND-enabling activities.
Financially, Shattuck had $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, up from $60.9 million a year earlier. First quarter 2026 research and development expenses were $10.9 million, general and administrative expenses were $4.6 million, and net loss was $14.8 million, or $(0.13) per basic and diluted share. The company expects existing cash, including potential proceeds from outstanding common stock warrants, to fund operations into 2029 based on current plans.
Shattuck Labs, Inc. will hold its 2026 virtual annual stockholder meeting on May 28, 2026 at 11:30 a.m. Eastern Time. Stockholders of record as of April 2, 2026, when 75,581,787 common shares were outstanding, may vote online on several governance and compensation items.
Investors are asked to elect three Class III directors to serve until the 2029 annual meeting, ratify KPMG LLP as independent auditor for the year ending December 31, 2026, and approve a non-binding advisory vote on executive pay and the frequency of future say‑on‑pay votes, where the Board recommends every one year.
The proxy also seeks approval of an amended and restated 2020 Equity Incentive Plan, which would fix the share pool at 14,123,126 shares plus a one-time 1,691,082-share increase and update the automatic annual increase to 4% of total capital stock from 2027 through 2030, helping maintain equity capacity for employees, directors and consultants.